Drugplain

Fomepizole 1.5 g/1.5mL

Fomepizole · INJECTION · Sagent Pharmaceuticals

1 Recall on Record
Plain English

Fomepizole is a injection containing fomepizole at 1.5 g/1.5mL, taken intravenous. Manufactured by Sagent Pharmaceuticals.

Key Facts

Brand Name
Fomepizole
Generic Name
Fomepizole
NDC Code (Product)
25021-829
Manufacturer
Sagent Pharmaceuticals
Strength
1.5 g/1.5mL
Dosage Form
INJECTION
Route
INTRAVENOUS
Marketing Status
Application #
ANDA216791
Drug Class
Antidote [EPC]
Marketing Start
11/15/2023

Recall History

1 Recall on Record
Class II03/09/2015

Navinta LLC

Lack of Assurance of Sterility. A recent FDA inspection reported GMP violations potentially impacting product quality and sterility.

TerminatedVoluntary: Firm initiated

Side Effects Reported to FDA

FDA FAERS database · These are reported events, not confirmed side effects

drug ineffective66 reports
toxicity to various agents50 reports
overdose37 reports
off label use32 reports
metabolic acidosis23 reports
hypotension18 reports
intentional overdose18 reports
hepatotoxicity17 reports
acute kidney injury16 reports
brain oedema16 reports

Full Prescribing Information

Source: FDA Drug Label (SPL)For healthcare professionals

Indications & Usage

INDICATIONS AND USAGE Fomepizole injection is indicated as an antidote for ethylene glycol (such as antifreeze) or methanol poisoning, or for use in suspected ethylene glycol or methanol ingestion, either alone or in combination with hemodialysis (see DOSAGE AND ADMINISTRATION ).

Dosage & Administration

DOSAGE AND ADMINISTRATION Do not use polycarbonate syringes or polycarbonate-containing needles (including polycarbonate filter needles) when diluting or administering fomepizole injection. Fomepizole can interact with polycarbonate, compromising the integrity of the syringe and/or needle component containing polycarbonate. Treatment Guidelines: If ethylene glycol or methanol poisoning is left untreated, the natural progression of the poisoning leads to accumulation of toxic metabolites, including glycolic and oxalic acids (ethylene glycol intoxication) and formic acid (methanol intoxication). These metabolites can induce metabolic acidosis, nausea/vomiting, seizures, stupor, coma, calcium oxaluria, acute tubular necrosis, blindness, and death. The diagnosis of these poisonings may be difficult because ethylene glycol and methanol concentrations diminish in the blood as they are metabolized to their respective metabolites. Hence, both ethylene glycol and methanol concentrations and acid base balance, as determined by serum electrolyte (anion gap) and/or arterial blood gas analysis, should be frequently monitored and used to guide treatment. Treatment consists of blocking the format

Contraindications

CONTRAINDICATIONS Fomepizole should not be administered to patients with a documented serious hypersensitivity reaction to fomepizole or other pyrazoles.

Drug Interactions

Drug Interactions: Oral doses of fomepizole (10 to 20 mg/kg), via alcohol dehydrogenase inhibition, significantly reduced the rate of elimination of ethanol (by approximately 40%) given to healthy volunteers in moderate doses. Similarly, ethanol decreased the rate of elimination of fomepizole (by approximately 50%) by the same mechanism. Reciprocal interactions may occur with concomitant use of fomepizole and drugs that increase or inhibit the cytochrome P450 system (e.g., phenytoin, carbamazepine, cimetidine, ketoconazole), though this has not been studied.

Adverse Reactions

ADVERSE REACTIONS The most frequent adverse events reported as drug-related or unknown relationship to study drug in the 78 patients and 63 normal volunteers who received fomepizole injection were headache (14%), nausea (11%), and dizziness, increased drowsiness, and bad taste/metallic taste (6% each). All other adverse events in this population were reported in approximately 3% or fewer of those receiving fomepizole injection and were as follows: Body as a Whole: Abdominal pain, fever, multiorgan system failure, pain during fomepizole injection, inflammation at injection site, lumbalgia/backache, hangover Cardiovascular: Sinus bradycardia/bradycardia, phlebosclerosis, tachycardia, phlebitis, shock, hypotension Gastrointestinal: Vomiting, diarrhea, dyspepsia, heartburn, decreased appetite, transient transaminitis Hemic/Lymphatic: Eosinophilia/hypereosinophilia, lymphangitis, disseminated intravascular coagulation, anemia Nervous: Lightheadedness, seizure, agitation, feeling drunk, facial flush, vertigo, nystagmus, anxiety, "felt strange", decreased environmental awareness Respiratory: Hiccups, pharyngitis Skin/Appendages: Application site reaction, rash Special Senses: Abnormal sme

Frequently Asked Questions

What is Fomepizole used for?

Fomepizole contains Fomepizole. It is a injection taken intravenous. Consult your doctor for specific uses.

Is Fomepizole a controlled substance?

Fomepizole is not classified as a controlled substance by the DEA.

What is the generic name for Fomepizole?

The generic name for Fomepizole is Fomepizole. There are 1 other brand versions of Fomepizole.

What is the NDC code for Fomepizole 1.5 g/1.5mL?

The NDC (National Drug Code) for Fomepizole 1.5 g/1.5mL is 25021-829, listed by Sagent Pharmaceuticals.

Product NDC

25021-829

Package NDC

25021-829-02

Not medical advice. Always consult your doctor or pharmacist before making any medication decisions.

Data from openFDA · Public domain (CC0 1.0)